Business

Cipher Pharmaceuticals Inc. to present at Rodman & Renshaw 16th Annual Global Investment Conference

MISSISSAUGA, ON , Sept. 3, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cip...

articleCipher Pharmaceuticals Inc.September 3, 20143/company/cipher-pharmaceuticals-inc/news/cipher-pharmaceuticals-inc-to-present-at-rodman-and-renshaw-16th-annual-global-investment-conference
Cipher Pharmaceuticals Inc. to present at Rodman & Renshaw 16th Annual Global Investment Conference

About this update from Cipher Pharmaceuticals Inc.

[{"type":"text","content":"\n\nMISSISSAUGA, ON, Sept. 3, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (\"Cipher\" or \"the Company\") today announced Shawn Patrick O'Brien, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 16th Annual Global Investment Conference, which is being held in New York City from  September 8-10 at the New York Palace Hotel. Mr. O'Brien will provide a corporate update and participate in a Q&A breakout session on Tuesday, September 9, 2014 at 9:35 AM ET in the Holmes 1 Salon.\n\nCipher's presentation will be available on their website www.cipherpharma.com and at http://bit.ly/Y9aot0. \n\nAbout Cipher Pharmaceuticals Inc.\n\nCipher is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. For our current marketed products, we are responsible for supplying our partners with commercial product. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed eight marketing partnerships, generating growing licensing revenue. \nSOURCE Cipher Pharmaceuticals Inc.\n\n\n\nCraig Armitage, Investor Relations, TMX Equicom, (416) 815-0700 ext 278, (416) 815-0080 fax, [email protected]; Shawn Patrick O'Brien, Chief Executive Officer, Cipher Pharmaceuticals, (905) 602-5840 ext 325, (905) 602-0628 fax, [email protected] CNW Group 2014","length":2691,"tagName":"div"}]

More updates from Cipher Pharmaceuticals Inc.